• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

测量 194 个国家多囊卵巢综合征的全球疾病负担:2017 年全球疾病负担研究。

Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.

机构信息

Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.

Department of Global Health, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China.

出版信息

Hum Reprod. 2021 Mar 18;36(4):1108-1119. doi: 10.1093/humrep/deaa371.

DOI:10.1093/humrep/deaa371
PMID:33501984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7970729/
Abstract

STUDY QUESTION

What is the current burden of polycystic ovary syndrome (PCOS) at the global, regional, and country-specific levels in 194 countries and territories according to age and socio-demographic index (SDI)?

SUMMARY ANSWER

Slight increases in age-standardized incidence of PCOS and associated disability-adjusted life-years (DALYs) were evidenced among women of reproductive age (15-49 years) from 2007 to 2017 at the global level, and in most regions and countries.

WHAT IS KNOWN ALREADY

No detailed quantitative estimates of the PCOS incidence and DALYs by age and SDI in these 194 countries and territories have been published previously.

STUDY DESIGN, SIZE, DURATION: An age- and SDI-stratified systematic analysis of the PCOS incidence and DALYs across 194 countries and territories has been performed.

PARTICIPANTS/MATERIALS, SETTING, METHODS: We used data from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2017 to estimate the total and age-standard PCOS incidence rates and DALYs rates among women of reproductive age in both 2007 and 2017, and the trends in these parameters from 2007 to 2017.

MAIN RESULTS AND THE ROLE OF CHANCE

Globally, women of reproductive age accounted for 1.55 million (95% uncertainty intervals (UIs): 1.19-2.08) incident cases of PCOS and 0.43 million (0.19-0.82) associated DALYs. The global age-standardized PCOS incidence rate among women of reproductive age increased to 82.44 (64.65-100.24) per 100 000 population in 2017, representing an increase of 1.45% (1.43-1.47%) from 2007 to 2017. The rate of age-standardized DALYs increased to 21.96 (12.78-31.15) per 100 000 population in 2017, representing an increase of 1.91% (1.89-1.93%) from 2007 to 2017. Over the study period, the greatest increase in the age-standardized PCOS incidence and DALYs rates were observed in the middle-SDI and high-middle SDI regions, respectively. At the GBD regional level, the highest age-standardized incidence and DALY rates in 2017 were observed in Andean Latin America, whereas the largest percentage increases in both rates from 2007 to 2017 were observed in Tropical Latin America. At the national level, Ecuador, Peru, Bolivia, Japan, and Bermuda had the highest age-standardized incidence rates and DALYs rates in both 2007 and 2017. The highest increases in both the age-standardized incidence rates and DALYs rates from 2007 to 2017 were observed in Ethiopia, Brazil, and China.

LIMITATIONS, REASONS FOR CAUTION: Although the GBD (2017) study aimed to gather all published and unpublished data, the limited availability of data in some regions might have led to the estimation of wide UIs. Additionally, the PCOS phenotype is complicated and the diagnostic criteria are constantly changing. Consequently, the incidence of PCOS might have been underestimated.

WIDER IMPLICATIONS OF THE FINDINGS

Knowledge about the differences in the PCOS burden across various locations will be valuable for the allocation of resources and formulation of effective preventive strategies.

STUDY FUNDING/COMPETING INTEREST(S): The study was supported by grants from the Innovative Talent Support Plan of the Medical and Health Technology Project in Zhejiang Province (2021422878), Ningbo Science and Technology Project (202002N3152), Ningbo Health Branding Subject Fund (PPXK2018-02), Sanming Project of Medicine in Shen-zhen (SZSM201803080), and National Social Science Foundation (19AZD013). No potential conflicts of interest relevant to this article were reported.

TRIAL REGISTRATION NUMBER

N/A.

摘要

研究问题

在全球 194 个国家和地区,根据年龄和社会人口指数(SDI),2007 年至 2017 年,15-49 岁生育年龄女性中多囊卵巢综合征(PCOS)的当前负担是多少,包括发病率和与疾病相关的伤残调整生命年(DALY)?

总结答案

在全球范围内,2007 年至 2017 年,生育年龄女性的年龄标准化 PCOS 发病率和相关 DALY 呈轻微上升趋势,在大多数地区和国家也是如此。

已知情况

以前没有发表过这些 194 个国家和地区中按年龄和 SDI 划分的 PCOS 发病率和 DALY 的详细定量估计。

研究设计、规模、持续时间:对全球 194 个国家和地区的 PCOS 发病率和 DALY 进行了年龄和 SDI 分层的系统分析。

参与者/材料、设置、方法:我们使用了全球疾病、伤害和危险因素研究(GBD)2017 年的数据,以估计生育年龄女性在 2007 年和 2017 年的总 PCOS 发病率和年龄标准化发病率以及相关 DALY 率,以及 2007 年至 2017 年期间这些参数的趋势。

主要结果和机会的作用

在全球范围内,生育年龄的女性中有 155 万例(95%不确定区间(UI):1.19-2.08)PCOS 新发病例和 43 万例(0.19-0.82)相关 DALY。2017 年,生育年龄女性的全球年龄标准化 PCOS 发病率上升至每 10 万人 82.44 例(64.65-100.24),比 2007 年增加了 1.45%(1.43-1.47%)。2017 年,年龄标准化 DALY 率上升至每 10 万人 21.96 例(12.78-31.15),比 2007 年增加了 1.91%(1.89-1.93%)。在研究期间,中 SDI 和高-中 SDI 地区的年龄标准化 PCOS 发病率和 DALY 率增幅最大。在全球区域水平上,2017 年安第斯拉丁美洲的年龄标准化发病率和 DALY 率最高,而 2007 年至 2017 年这两个率的百分比增幅最大的是热带拉丁美洲。在国家层面上,2007 年和 2017 年,厄瓜多尔、秘鲁、玻利维亚、日本和百慕大的年龄标准化发病率和 DALY 率最高。2007 年至 2017 年,发病率和 DALY 率增幅最大的是埃塞俄比亚、巴西和中国。

限制因素、谨慎的原因:尽管 GBD(2017)研究旨在收集所有已发表和未发表的数据,但在某些地区数据的有限可用性可能导致广泛的不确定区间。此外,PCOS 表型复杂,诊断标准不断变化。因此,PCOS 的发病率可能被低估了。

研究结果的更广泛意义

了解不同地区 PCOS 负担的差异对于资源配置和制定有效的预防策略将是有价值的。

研究资金/利益冲突:这项研究得到了浙江省医疗卫生技术项目创新人才支持计划(2021422878)、宁波科技项目(202002N3152)、宁波健康品牌主题基金(PPXK2018-02)、深圳三铭项目(201803080)和国家社会科学基金(19AZD013)的资助。没有与本研究相关的潜在利益冲突。

试验注册编号

无。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/774dc2e236e9/deaa371f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/ce4124c3e8d0/deaa371f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/90a0a5975068/deaa371f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/774dc2e236e9/deaa371f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/ce4124c3e8d0/deaa371f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/90a0a5975068/deaa371f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad51/7970729/774dc2e236e9/deaa371f3.jpg

相似文献

1
Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.测量 194 个国家多囊卵巢综合征的全球疾病负担:2017 年全球疾病负担研究。
Hum Reprod. 2021 Mar 18;36(4):1108-1119. doi: 10.1093/humrep/deaa371.
2
Global, regional, and national burden of infertility attributable to PCOS, 1990-2019.全球、区域和国家多囊卵巢综合征所致不孕负担,1990-2019 年。
Hum Reprod. 2024 Jan 5;39(1):108-118. doi: 10.1093/humrep/dead241.
3
Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990-2019.多囊卵巢综合征在 204 个国家和地区的流行率、发病率和残疾生存年数,1990-2019 年。
Hum Reprod. 2022 Jul 30;37(8):1919-1931. doi: 10.1093/humrep/deac091.
4
Global, regional, and national burden of premenstrual syndrome, 1990-2019: an analysis based on the Global Burden of Disease Study 2019.全球、区域和国家经前期综合征负担,1990-2019 年:基于 2019 年全球疾病负担研究的分析。
Hum Reprod. 2024 Jun 3;39(6):1303-1315. doi: 10.1093/humrep/deae081.
5
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.195 个国家和地区 1990-2017 年食管痛的全球、区域和国家负担及其可归因风险因素:2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597. doi: 10.1016/S2468-1253(20)30007-8. Epub 2020 Apr 1.
6
The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study.2019 年全球 195 个国家和地区因超重导致的疾病负担:基于全球疾病负担研究的分析。
PLoS Med. 2020 Jul 28;17(7):e1003198. doi: 10.1371/journal.pmed.1003198. eCollection 2020 Jul.
7
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.全球、地区和国家残疾调整生命年(DALYs)用于 333 种疾病和伤害以及 195 个国家和地区的健康期望寿命(HALE),1990-2016 年:全球疾病负担研究 2016 年的系统分析。
Lancet. 2017 Sep 16;390(10100):1260-1344. doi: 10.1016/S0140-6736(17)32130-X.
8
Study of Burden in Polycystic Ovary Syndrome at Global, Regional, and National Levels from 1990 to 2019.1990年至2019年全球、区域和国家层面多囊卵巢综合征负担研究
Healthcare (Basel). 2023 Feb 14;11(4):562. doi: 10.3390/healthcare11040562.
9
The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017.全球、地区和国家 195 个国家/地区 1990-2017 年胃癌负担:2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0. Epub 2019 Oct 21.
10
The epidemiology of pregnancy loss: global burden, variable risk factors, and predictions.妊娠丢失的流行病学:全球负担、可变危险因素和预测。
Hum Reprod. 2024 Apr 3;39(4):834-848. doi: 10.1093/humrep/deae008.

引用本文的文献

1
Global and Chinese epidemiologic study of polycystic ovary syndrome in women of childbearing age, 1990-2021, and projections to 2035: Based on the Global Burden of Disease 2021 study.1990 - 2021年全球及中国育龄期女性多囊卵巢综合征的流行病学研究及2035年预测:基于《2021年全球疾病负担》研究
PLoS One. 2025 Aug 19;20(8):e0329090. doi: 10.1371/journal.pone.0329090. eCollection 2025.
2
Global, regional, and national prevalence and trends of gynecological diseases among women of childbearing age from 1990 to 2021: An analysis of the global burden of disease study 2021.1990年至2021年全球育龄妇女妇科疾病的全球、区域和国家患病率及趋势:全球疾病负担研究2021分析
PLoS One. 2025 Aug 1;20(8):e0329336. doi: 10.1371/journal.pone.0329336. eCollection 2025.
3

本文引用的文献

1
A systematic review of global health capacity building initiatives in low-to middle-income countries in the Middle East and North Africa region.中东和北非地区中低收入国家全球卫生能力建设倡议的系统评价。
Global Health. 2020 Jul 3;16(1):56. doi: 10.1186/s12992-020-00585-0.
2
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990-2017.钙化性主动脉瓣和退行性二尖瓣疾病的全球、区域和国家负担,1990-2017 年。
Circulation. 2020 May 26;141(21):1670-1680. doi: 10.1161/CIRCULATIONAHA.119.043391. Epub 2020 Mar 29.
3
Adolescent polycystic ovary syndrome according to the international evidence-based guideline.
Decoding androgen excess in polycystic ovary syndrome: Roles of insulin resistance and other key intraovarian and systemic factors.解读多囊卵巢综合征中的雄激素过多:胰岛素抵抗及其他关键的卵巢内和全身因素的作用
World J Diabetes. 2025 Jul 15;16(7):108789. doi: 10.4239/wjd.v16.i7.108789.
4
Temporal Trends of Polycystic Ovary Syndrome Burden in the East and Southeast Asia from 1990 to 2021: An Analysis from the Global Burden of Disease Study 2021.1990年至2021年东亚和东南亚多囊卵巢综合征负担的时间趋势:来自《2021年全球疾病负担研究》的分析
Int J Womens Health. 2025 Jul 15;17:2097-2108. doi: 10.2147/IJWH.S523350. eCollection 2025.
5
Application of ChatGPT-based artificial intelligence in the diagnosis and management of polycystic ovary syndrome.基于ChatGPT的人工智能在多囊卵巢综合征诊断与管理中的应用
BMC Med Inform Decis Mak. 2025 Jul 18;25(1):271. doi: 10.1186/s12911-025-03114-4.
6
The PCOS Phenotypes in Unselected Populations (P-PUP) study: participant clinical features and data harmonization on analysis of individual participant data.非选择人群中的多囊卵巢综合征表型(P-PUP)研究:个体参与者数据分析中的参与者临床特征与数据协调
BMC Med. 2025 Jul 15;23(1):420. doi: 10.1186/s12916-025-04221-9.
7
Changes in the comprehensive unassisted pregnancy rate as a possible marker of declining human fecundity.综合自然受孕率的变化作为人类生育力下降的一个可能指标。
Sci Rep. 2025 Jul 4;15(1):23916. doi: 10.1038/s41598-025-08332-4.
8
Effect of pre-treatment with oral short-acting contraceptives on assisted reproductive technology outcomes in patients with polycystic ovary syndrome: a meta-analysis.口服短效避孕药预处理对多囊卵巢综合征患者辅助生殖技术结局的影响:一项荟萃分析。
Front Endocrinol (Lausanne). 2025 Jun 5;16:1545508. doi: 10.3389/fendo.2025.1545508. eCollection 2025.
9
Economic impact of the Elecsys anti-Müllerian hormone Plus immunoassay for anti-Müllerian hormone testing as part of polycystic ovary syndrome assessment in the United Kingdom.在英国,作为多囊卵巢综合征评估一部分的抗苗勒管激素检测中,Elecsys抗苗勒管激素Plus免疫测定法的经济影响。
PLoS One. 2025 Jun 17;20(6):e0326162. doi: 10.1371/journal.pone.0326162. eCollection 2025.
10
Endocrine-disrupting chemicals and female reproductive health: a growing concern.内分泌干扰化学物质与女性生殖健康:日益受到关注。
Nat Rev Endocrinol. 2025 May 22. doi: 10.1038/s41574-025-01131-x.
青少年多囊卵巢综合征的国际循证指南。
BMC Med. 2020 Mar 24;18(1):72. doi: 10.1186/s12916-020-01516-x.
4
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortium.全球农业队列人群呼吸健康结局的性别差异:AGRICOH 联盟的研究结果。
J Agromedicine. 2021 Apr;26(2):97-108. doi: 10.1080/1059924X.2020.1713274. Epub 2020 Mar 17.
5
Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study.火灾、高温和热物质致伤的流行病学:来自 2017 年全球疾病负担研究的全球、区域和国家发病率和死亡率估计
Inj Prev. 2020 Oct;26(Supp 1):i36-i45. doi: 10.1136/injuryprev-2019-043299. Epub 2019 Dec 18.
6
Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017.1990 - 2017年195个国家和地区不孕症的全球、区域和国家患病率及伤残调整生命年:全球疾病负担研究的结果,2017年
Aging (Albany NY). 2019 Dec 2;11(23):10952-10991. doi: 10.18632/aging.102497.
7
[Towards an effective assessment of the sustainability of health interventions].迈向对健康干预措施可持续性的有效评估
Ig Sanita Pubbl. 2019 May-Jun;75(3):189-199.
8
Curtailing PCOS.多囊卵巢综合征的治疗。
Pediatr Res. 2020 Jan;87(2):353-361. doi: 10.1038/s41390-019-0615-1. Epub 2019 Oct 18.
9
Healthy China 2030: moving from blueprint to action with a new focus on public health.《“健康中国2030”规划纲要》:从蓝图迈向行动,重新聚焦公共卫生。
Lancet Public Health. 2019 Sep;4(9):e447. doi: 10.1016/S2468-2667(19)30160-4.
10
The diagnosis and treatment of PCOS in adolescents: an update.多囊卵巢综合征青少年患者的诊断与治疗:最新进展。
Curr Opin Pediatr. 2019 Aug;31(4):562-569. doi: 10.1097/MOP.0000000000000778.